Nilotinib Powder

제품 세부 정보

Nilotinib powder is a second-generation, next-generation targeted drug developed and sold by Novartis in Switzerland for the treatment of chronic myeloid leukemia. Raw powder antiacncer nilotinib powder, methyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate is a key intermediate of the chemotherapeutic drug nilotinib. The drug is safe and effective in the treatment of chronic myeloid leukemia/chronic myeloid leukemia patients taking imatinib for drug resistance. It is a tyrosine kinase inhibitor, and its content mainly inhibits BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11, ZAK kinases, etc. Dashina (nilotinib) is a new type of targeted tumor therapy drug, which has a significant effect on chronic myeloid leukemia (CML) patients who are resistant or intolerant to Gleevec (imatinib).

건강상의 이점

Nilotinib is a first-line oral targeted therapy for the treatment of chronic myeloid leukemia/chronic myeloid leukemia (CML).

• Treatment of newly diagnosed Philadelphia chromosome positive (Ph+) adult chronic myeloid leukemia in the chronic phase.
• Treatment of Philadelphia chromosome-positive chronic myeloid leukemia in blast phase and accelerated phase.
• Treatment of chronic myeloid leukemia in the chronic phase that has been treated with interferon Chemicalbook.
• Children with chronic myeloid leukemia who have relapsed after myelosuppression or who are ineffective in interferon therapy.
• Treatment of KIT(CD117)-positive inoperable or metastatic malignant gastrointestinal stromal tumors.